Adbry (Tralokinumab-ldrm): Side Effects, Uses, Interactions, Warnings

Adbry

Generic Name: Tralokinumab-ldrm

Brand Names: Adbry

Ingredients: Tralokinumab-ldrm

Drug Class: Monoclonal antibodies

Controlled Status: Not a Controlled Substance

Availability: Prescription Medication only

What is Adbry (Tralokinumab-ldrm)? 

Adbry (tralokinumab-ldrm) is a monoclonal antibody that targets and blocks interleukin-13 (IL-13), a protein that plays a key role in the inflammation and skin barrier dysfunction that occur in eczema.

It is a biologic medication used to treat moderate-to-severe atopic dermatitis (eczema) in adults. Adbry is administered as a subcutaneous injection every 2 to 4 weeks. It is generally well-tolerated, with the most common side effects being mild and temporary.

The most common side effects of Adbry are mild and temporary. The most common side effects include Injection site reactions, Upper respiratory infections, Conjunctivitis (pink eye), Headache, Fatigue, Eosinophilia (high white blood cell count). Serious side effects of Adbry are rare. However, Adbry can increase the risk of allergic reactions, including anaphylaxis. Adbry can also increase the risk of serious infections.

What is Adbry (Tralokinumab-ldrm) Used for?

Adbry is indicated for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Adbry is administered as a subcutaneous injection every 2 to 4 weeks. It is generally well-tolerated, with the most common side effects being mild and temporary. It has shown to be effective in clinical trials at reducing eczema symptoms and improving skin clearance. It is an important treatment option for adults with moderate-to-severe eczema who have not responded well to other therapies.

How does Adbry (Tralokinumab-ldrm) Work?

Adbry (tralokinumab) is classified as a Monoclonal antibodies. It binds to interleukin-13 (IL-13), a protein within your immune system known to trigger inflammation. Adbry acts by inhibiting the function of IL-13, effectively reducing inflammation in the skin. This mechanism assists in alleviating symptoms associated with eczema or atopic dermatitis, specifically addressing skin inflammation and itchiness.

Adbry (Tralokinumab-ldrm) Dosage

The recommended initial dose is 600 mg, which consists of four injections of 150 mg each, followed by a maintenance dosage of 300 mg, administered as two injections of 150 mg every other week. After 16 weeks of treatment, patients weighing below 100 kg, who achieve visibly clear or nearly clear skin, may consider a reduced dosage of 300 mg every 4 weeks.

This regimen is primarily employed for treating moderate-to-severe atopic dermatitis in adult patients whose condition is not effectively managed by topical prescription therapies or when these therapies are not recommended.

What are the Side Effects of Adbry (Tralokinumab-ldrm)? 

Seek immediate medical attention if you encounter any of the subsequent symptoms. These serious manifestations encompass a severe allergic reaction (anaphylaxis), which might present as difficulty breathing, throat tightness, hives, itching, rapid heartbeat, dizziness, nausea, stomach discomfort, or swelling in the face or tongue. Certain side effects might ameliorate as your body acclimates to the medication. Notify your healthcare provider promptly if these symptoms persist or exacerbate.

Common Adverse Effects Commonly observed side effects include upper respiratory infections (24%), pink eye (8%), and reactions at the injection site, characterized by pain, redness, or swelling (7%). Allergic reactions like skin rash, itching, swelling of the face, lips, tongue, or throat, as well as eye discomfort, redness, irritation, or blurry vision. Side effects that generally do not necessitate immediate medical attention and should be reported to your care team only if they persist or become bothersome include injection site pain, redness, or irritation, runny or congested nose, and sore throat.

For more information about Adbry Side Effects

How to Use Adbry (Tralokinumab-ldrm)?

Refer to the comprehensive “Instructions for Use” provided with Adbry for guidance on how to prepare, administer, and appropriately store and discard used Adbry prefilled syringes. Follow your healthcare provider’s prescription precisely when using Adbry . Your healthcare provider will specify the correct dosage and timing for administering Adbry .

Adbry is available as a single-dose (150 mg) prefilled syringe equipped with a needle guard, administered as a subcutaneous injection. If your healthcare provider approves, you or a caregiver can be trained on the proper method to prepare and administer ADBRY. Do not attempt to administer Adbry until your healthcare provider has demonstrated the correct procedure.

If a dose is missed, administer it as soon as possible, then continue with the subsequent dose as per your regular schedule. In the event of an accidental overdose of Adbry , contact Poison Control at 1-800-222-1222. Your healthcare provider might prescribe additional medications to be used in conjunction with Adbry . Ensure that you use these other prescribed medicines as directed by your healthcare provider.

What Happens if I Miss a Dose of Adbry (Tralokinumab-ldrm)? 

If you miss a dose, take it as soon as you can. Then continue taking the medication at your regular scheduled time.

What Happens if I Overdose Adbry (Tralokinumab-ldrm)? 

In case of a medical emergency, please seek immediate medical assistance or contact the Poison Help Line at 1-800-222-1222. Information is also available online at poisonhelp.org. Nevertheless, if you are experiencing severe symptoms, please do not hesitate to dial 911 (or your Local Emergency Number) immediately or proceed to the nearest emergency room for immediate medical attention. Your safety and well-being are paramount.

Pros and Cons of Adbry (Tralokinumab-ldrm)

Pros	Cons
Works effectively for moderate-to-severe eczema	Available only as a brand name, which may be costly
Administered every 2 to 4 weeks	Could be challenging for some to self-administer properly
Offered as prefilled syringes	Not suitable for use in children
Low risk of adverse effects	Not thoroughly studied in individuals aged 65 years and older, uncertain response compared to younger people
Convenient storage at room temperature for 2 weeks	Reserved for individuals with moderate-to-severe eczema who’ve exhausted or can’t use topical therapy

Interaction Between Adbry (Tralokinumab-ldrm) and other Drugs

What are the Risks and Warnings for Adbry (Tralokinumab-ldrm)?

Adbry (Tralokinumab-ldrm) and Allergy Warning

Allergic reactions, known as hypersensitivity, can occur with Adbry, including severe reactions such as anaphylaxis. Discontinue Adbry immediately and seek urgent medical attention or contact your healthcare provider if you experience any of the following symptoms:

• Breathing difficulties
• Swelling of the face, mouth, and tongue
• Hives
• Itching
• Fainting, dizziness, feeling lightheaded (signs of low blood pressure)
• Skin rash
• Inflammation of the eye and eyelids, characterized by redness, swelling, and itching
• Reactions at the injection site

Warning with People with Certain Health Conditions

• Sensitivity Reactions: Instances of hypersensitivity, including anaphylaxis and angioedema, have been documented following the administration of Adbry. In the event of a severe hypersensitivity reaction, discontinue Adbry immediately and commence appropriate therapy.

• Eye Conditions: Individuals with atopic dermatitis who received Adbry experienced a higher occurrence of conjunctivitis and keratitis. Among these eye conditions, conjunctivitis was the most frequently reported. Patients should be advised to promptly inform their healthcare provider about the onset of new or worsening eye symptoms.

• Parasitic Infections: Address pre-existing helminth infections in patients before commencing Adbry treatment. If patients acquire an infection while on ADBRY and do not respond to antihelminth treatment, suspend Adbry treatment until the infection resolves.

• Live Vaccine Infection Risk: Adbry may modify a patient’s immune response, heightening the infection risk following live vaccine administration. Before starting Adbry therapy, ensure all age-appropriate vaccinations align with current immunization guidelines. Avoid administering live vaccines to patients undergoing ADBRY treatment. Limited data are available regarding the simultaneous administration of ADBRY with non-live vaccines.

Warning with other Groups

Adbry (Tralokinumab-ldrm) and Breastfeeding

Because this medication is a large protein molecule, it is expected that the quantity transferred to breast milk would likely be minimal. Additionally, the infant’s digestive system may partially break down the drug, resulting in minimal absorption by the infant.

According to some experts, a decision should be thoughtfully weighed regarding whether to discontinue breastfeeding or halt the use of this drug, considering the therapy’s importance for the mother and the benefits of breastfeeding for the child.

There is no available information about the presence of this drug in human milk, its effects on breastfed infants, or its influence on milk production. While maternal immunoglobulin G (IgG) is present in breast milk, the impact of localized gastrointestinal exposure and limited systemic exposure to this drug on the breastfed infant remains unknown.

Adbry (Tralokinumab-ldrm) and Pregnancy

Human immunoglobulin G (IgG) antibodies have the capability to traverse the placenta, potentially leading to the transfer of this medication from the mother to the fetus. Limited available data on the usage of this drug in pregnant women complicates the assessment of associated risks, such as potential harm to the fetus or reproductive effects. Notably, controlled studies in human pregnancies are lacking.

According to the US FDA, this drug does not have a designated pregnancy category due to modifications in the pregnancy labeling regulations for prescription drugs.

Expiration, Storage and Disposal

Store the tralokinumab injection in the original container, securely closed, and away from children. Keep it refrigerated and shielded from light. You may also store the injection at room temperature (up to 77°F [25°C]) for up to 14 days, ensuring it’s protected from light. If kept at room temperature for over 14 days and unused, dispose of the injection. Avoid freezing it and discard any medication that has been frozen.

It’s crucial to keep all medicines out of sight and inaccessible to children, as many containers are not child-resistant and can be easily opened by young children. Safeguard against accidental poisoning by consistently using safety caps and storing medications in a safe, elevated location that is out of children’s sight and reach. http://www.upandaway.org

Dispose of unnecessary medications in a manner that prevents accidental consumption by pets, children, or other individuals. Never flush medication down the toilet. Instead, consider utilizing a medicine take-back program. Consult your pharmacist or local waste management facility to explore take-back programs available in your area. For further guidance on safe medicine disposal, visit the FDA’s Safe Disposal of Medicines website (http://goo.gl/c4Rm4p).

Images

What are the Alternatives of Adbry (Tralokinumab-ldrm)?

• Dupixent (dupilumab)
• Eucrisa (crisaborole)
• Opzelura (ruxolitinib cream)
• Cibinqo (abrocitinib)

FAQs